Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025 More than half of the patients required for the Phase 3 REGEN-006 (PROACT 1) accelerated approval analysis using estimated glomerular filtration rate (eGFR) slope have been enrolled; topline results anticipated in Q2 2027 Ended the third quarter with $272 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027WINSTON-SALEM, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported financial results for the third quarter ended September 30, 2025, and...

Revenue: $7.4 million, 41% YoY increaseNet Income: $0.6 millionTransaction Volumes up 43% YoYBitcoin Investment Treasury Holdings: 1,526 BTC1 PHOENIX, Nov. 10, 2025 (GLOBE NEWSWIRE) — Fold Holdings, Inc. (NASDAQ: FLD) (“Fold”, “we”, or “our”), the first publicly traded bitcoin financial services company, today announced financial results for the third quarter ended September 30, 2025. Financial HighlightsRevenue: $7.4 million; 41% YoY increase Net Income: $0.6 million Adjusted EBITDA2 (Loss): ($4.2) million Earnings Per Share: $0.01 per share Adjusted EBITDA (Loss) Per Share2: ($0.09) per share Bitcoin Investment Treasury Holdings1: 1,526 BTCKey Operating MetricsTotal Transaction Volume: $235 million; 43% YoY increase Total Active Accounts: 625,000+, added +7,500 new accounts in the quarter Total Verified Accounts: 82,000+,...

HOUSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) — Occidental (NYSE: OXY) today announced its third quarter 2025 financial results. The earnings release and accompanying financial schedules can be accessed via the Investor Relations section of the company’s website at oxy.com. The earnings release is also available on the U.S. Securities and Exchange Commission’s website at sec.gov. The company will hold a conference call to discuss the results on Tuesday, November 11, 2025, at 1 p.m. Eastern/12 p.m. Central. The conference call may be accessed by calling 1-866-871-6512 (international callers dial 1-412-317-5417) or via webcast at oxy.com/investors. Participants may pre-register for the conference call at https://dpregister.com/sreg/10202923/ffe6d67319. A recording of the webcast will be posted on the Investor Relations section of the company’s...

GEORGE TOWN, Cayman Islands, Nov. 10, 2025 (GLOBE NEWSWIRE) — Consolidated Water Co. Ltd. (NASDAQ Global Select Market: CWCO), a leading designer, builder and operator of advanced water supply and treatment plants, reported results for the third quarter ended September 30, 2025. All comparisons are to the same prior year period unless otherwise noted. Consolidated Water will hold a conference call at 11:00 a.m. Eastern time tomorrow to discuss the results (see dial-in information below). Third Quarter 2025 Financial SummaryTotal revenue increased 5% to $35.1 million. Retail revenue increased 2% to $7.8 million. Bulk revenue decreased 4% to $8.4 million. Services revenue increased by 13% to $14.3 million as construction revenue increased 50% to $6.4 million and operations and maintenance (O&M) revenue increased 3% to $7.7...

Continued Investment in our Long-Term Strategic Plan NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) — Vroom, Inc. (Nasdaq:VRM) today announced financial results for the third quarter ended September 30, 2025. HIGHLIGHTS OF THIRD QUARTER 2025$59.2 million consolidated total available liquidity(1) as of September 30, 2025, consisting of:$12.4 million cash and cash equivalents         $11.8 million of liquidity available to UACC under the warehouse credit facilities $35.0 million of available liquidity from delayed draw facility, further strengthening our liquidity position to execute our long-term strategy$(27.1) million net loss from continuing operations for the three months ended September 30, 2025 $(25.7) million adjusted net loss(2) for the three months ended September 30, 2025$(15.3) million unfavorable mark-to-market for...

Secured $147.6 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by $71.6 million in committed capital from Medtronic and Ligand, as well as $30 million from TerumoInitiated patient enrollments in the Virtue Trial evaluating Virtue® Sirolimus AngioInfusion™ Balloon (“Virtue SAB”) trial versus commercially available paclitaxel-coated balloonDemonstrated partnership-driven business model execution with expanded strategic collaboration with Medtronic and new right of first refusal agreement with TerumoNEW HOPE, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing...

Delivered ~21% worldwide revenue growth, ~5% adjusted EBITDA margin, and positive cash from operating activities in the quarter Third Quarter 2025 Financial Highlights (all comparisons are to the prior year period)Worldwide revenue of $48.7 million, representing growth of 20.6%   U.S. revenue of $46.4 million, representing growth of 21.2% Gross margin of 79.8%, representing an improvement of 75 basis points Net loss of $4.6 million, representing an improvement of 30.6%   Positive adjusted EBITDA of $2.3 million Positive cash from operating activities of $2.3 million $145.7 million in cash and equivalentsRecent Operational Highlights (any comparisons are to the prior year period)1,530 active U.S. physicians, representing growth of 27%       $2.1 million in trailing 12-month average revenue per territory, representing an increase...

Q3 Annual Subscription Revenue Up 11.2% (Currency Neutral 9.3%), Representing 58.4% of Total Revenue Strong Q3 Profitability: 9.0% Net Income margin and 32.8% Adjusted EBITDA margin Updates 2025 Revenue and Adjusted EBITDA Guidance Finalizes Strategic Partnerships to Integrate Getty Images Content into Emerging AI PlatformsNEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) — Getty Images Holdings, Inc. (“Getty Images” or the “Company”) (NYSE: GETY), a preeminent global visual content creator and marketplace, today reported financial results for the third quarter ended September 30, 2025. “Third quarter results were in line with our expectations, with top-line growth flattening due to challenging year-over-year comparisons against last year’s robust event calendar,” said Craig Peters, Chief Executive Officer at Getty Images. “We were pleased...

Signed Definitive Agreement to Acquire eSelf.aiRepurchased 14.4 million shares of common stock / $16.6 million of common stock from Goldman Sachs NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) — Kaltura, Inc. (Nasdaq: KLTR, “Kaltura” or the “Company”), the Video Experience Cloud, today announced financial results for the third quarter ended September 30, 2025, as well as outlook for the fourth quarter and full year 2025. “We exceeded the upper end of all our third quarter guidance ranges, delivering record adjusted EBITDA profit, and strong operating cash flow,” said Ron Yekutiel, Co-founder, Chairman, President, and CEO of Kaltura. “We’ve entered the fourth quarter of the year with a strong pipeline and continue to project growth in new bookings in the coming quarter, supported by continued customer consolidation around our platform...

ZUG, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) —Oculis accelerates its portfolio development with Privosegtor moving into the PIONEER pivotal program in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) following positive FDA meeting OCS-01 DIAMOND Phase 3 trials in diabetic macular edema (DME) remain on track for topline results expected in Q2 2026 Licaminlimab PREDICT-1 registrational trial, the first genotype-based trial to drive precision medicine in dry eye disease (DED), expected to start in Q4 2025 Cash, cash equivalents and short-term investments of $182.2 million as of September 30, 2025 plus recent $110 million financing, extend cash runway into 2029Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations...